Hormonal
Intermittent administration of rapamycin (e.g., 2 mg/kg every 5 days) extends lifespan in mice while minimizing metabolic and immunological side effects associated with chronic dosing.
For healthy adults seeking longevity interventions, intermittent dosing of rapamycin (specifically 2mg/kg every 5 days) appears to offer a superior risk-benefit profile compared to daily dosing. This schedule extends lifespan in mice and avoids the metabolic and immune suppression seen with chronic use. While human trials are ongoing, this protocol represents the current best evidence for mitigating rapamycin's known side effects while preserving its anti-aging benefits.
Single doses of 2-mg/kg rapamycin injected once every 5 days was the most frequent treatment regimen that did not impair glucose homeostasis; this dosing regimen also had a reduced impact on the immune system while still significantly inhibiting mTORC1 in many tissues (98).
Why this rating
Based on multiple mouse studies (wild-type and heterogeneous) showing lifespan extension, though human data is limited to short-term metabolic/immune markers.
Source
Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island
Sebastian I. Arriola Apelo et al. · The Journals of Gerontology Series A · 2016
DOI 10.1093/gerona/glw090
More from this paper
- Chronic inhibition of mTORC2 by rapamycin causes metabolic dysfunction (glucose intolerance, insulin resistance) and immunosuppression, acting as the primary barrier to its use as an anti-aging therapy.Strong
- Rapamycin exhibits sexual dimorphism in efficacy, extending lifespan significantly more in female mice than in male mice.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →